Loading organizations...
§ Private Profile · San Diego
Biotechnology company developing small molecule drugs using C-H bond activation for immunology, oncology, and hard-to-drug targets
Key people at Architect Therapeutics.
Established in 2023 by founders Richard A. Heyman and Jin-Quan Yu, Architect Therapeutics is a California biotechnology company led by Chief Executive Officer Angie You that develops small molecule drugs utilizing carbon-hydrogen bond activation technology. This innovative scientific approach allows the enterprise to rapidly edit these carbon and hydrogen bonds within molecules, enabling the creation of novel 3D drug architectures specifically designed for hard-to-drug targets. The organization operates an integrated platform that combines both covalent and noncovalent discovery methods to feed proprietary chemical libraries into advanced screening applications. By transforming common carbon-hydrogen bonds into structural building blocks, these specialized screening processes are directed toward developing first- and best-in-class oral therapies. Ultimately, the company focuses its pioneering medical research on addressing chemically challenging and biologically validated targets primarily within the immunology and oncology disease sectors.
Architect Therapeutics is a biotechnology company developing oral small-molecule therapies for challenging targets in immunology, oncology, and neuroscience using breakthrough C-H bond activation chemistry.[1][3] Founded in 2023, it raised a $120M Series A led by ARCH Venture Partners to exploit dormant C-H bonds—the most common in small molecules—into novel 3D drug architectures via an integrated discovery engine combining DNA-encoded libraries (DEL), nano-scale synthesis, and chemical proteomics.[1][3] The company serves patients with hard-to-treat diseases by targeting validated biology, with its lead immunology program (a PPI disruptor) entering discovery candidacy this year, demonstrating early pipeline momentum.[1]
This platform enables covalent and non-covalent drug discovery with atomic-level precision, addressing "undruggable" targets faster than traditional methods.[3] Backed by Scripps Research pioneers Jin-Quan Yu and Ben Cravatt, Architect aims for first- and best-in-class oral therapies, positioning it for rapid progression in high-unmet-need areas.[1][3]
Architect Therapeutics was incorporated on May 31, 2023, in San Diego, California, as a stock corporation.[7] It emerged from transformative chemistry breakthroughs by founder Jin-Quan Yu at Scripps Research, who developed C-H bond activation techniques over decades, enabling selective editing of the most abundant yet inert bonds in small molecules.[1][3] Co-founder Ben Cravatt complemented this with chemical proteomics expertise, powering the company's screening engine.[1]
Serial biotech entrepreneur Richard Heyman, PhD, co-founded and chairs the company, drawing from his track record founding firms like Aragon (acquired by J&J), Seragon (acquired by Roche), and recent chairmanships at Vividion (Bayer), Amunix (Sanofi), and RayzeBio (BMS).[5] The $120M Series A, led by ARCH Venture Partners shortly after formation, provided immediate firepower, with early traction from a validated pipeline including immunology, oncology, and neuroscience targets.[1][3] This blend of academic innovation and venture muscle marked a pivotal launch into precision drug design.
Architect rides the wave of precision chemistry revolutionizing small-molecule drug discovery, targeting the ~90% of proteins deemed undruggable by traditional methods.[3] Timing aligns with surging demand for oral therapies in immunology and oncology, fueled by successes like covalent inhibitors (e.g., BTK drugs) and advances in proteomics.[1][3] Market forces favor it: biotech funding rebound post-2022 downturn, ARCH's track record in chemistry platforms (e.g., Vividion), and regulatory tailwinds for novel modalities amid pipeline attrition rates over 90% in early discovery.[1][5]
The company influences the ecosystem by open-sourcing C-H activation paradigms—Yu's work is hailed as a "paradigm shift" in synthetic logic—potentially accelerating industry-wide innovation in 3D chemical space and covalent drugging.[3] As a San Diego hub player, it bolsters the region's biotech cluster alongside Scripps and ARCH-backed ventures.
Architect's near-term catalysts include advancing its immunology lead into clinic and expanding the pipeline with C-H-enabled hits, leveraging its well-capitalized $120M war chest for 3-5 years of runway.[1] Trends like AI-drug discovery synergies and covalent expansion will amplify its engine, while partnerships (e.g., with Big Pharma for oncology assets) could drive milestones. Influence may evolve from platform pioneer to multi-asset creator, potentially mirroring Vividion's Bayer buyout path under Heyman's helm.[5]
This positions Architect to redefine oral drugging, turning chemistry barriers into therapeutic breakthroughs for patients long underserved by existing tools.
Key people at Architect Therapeutics.
